By this regimen, the total duration of the treatment (including the “taper” phase) is 12 weeks. Response to therapy should be gauged comprehensively, based on objective criteria, such as improvement in liver function tests (biochemical), resolution of jaundice, dry mouth and eyes(clinical), and the disappearance of bile duct strictures or a return to a normal-looking pancreas on cross-sectional imaging (radiological).16 It

is important not to gauge response to corticosteroid treatment on subjective symptoms, such improvement in the patients’ energy, as this is unreliable and potentially misleading. There is an opinion that routine bile duct stenting is unnecessary to treat strictures due to AIP, but if stents are placed, corticosteroid therapy Venetoclax order often allows their removal at 4 weeks. Changes in serum IgG4 levels vary with treatment and should not be used as a criterion to determine response to therapy. Between 30% and 50% of patients with AIP will relapse after the initial course of corticosteroid therapy.14 This forms the

rational for low-dose maintenance therapy in Japan.39 We do not advocate such use of long-term, low-dose corticosteroid therapy for two reasons. First, up to 70% of patients will not relapse, and thus, in this majority of cases, routine low-dose corticosteroid maintenance therapy is unnecessary.18 Second, long-term corticosteroid, even at low doses, has multiple adverse consequences (especially on bone and metabolic health) that unfavorably sways the risk-benefit profile for patients with AIP. Disease relapse can further be subdivided https://www.selleckchem.com/products/AZD2281(Olaparib).html into clinical (weight loss, jaundice, and abdominal discomfort), biochemical (elevated liver tests), or radiological relapse (enlarged pancreas, presence of new duct strictures).18,40 Etofibrate Clinical relapse is the most consequential and often will necessitate a second full course of corticosteroid therapy. It is important to keep in mind that clinical

relapse can occur in any of the other organs involved in AIP. In our practice, we advocate the addition of an immunomodulator, such as azathioprine (2–2.5 mg/kg), either as maintenance therapy after the first relapse or as maintenance therapy at presentation if there is proximal bile duct involvement. In either instance, this is always in addition to the standard course of corticosteroid therapy. If the patient is clinically asymptomatic, there is no role for routine abdominal imaging or monitoring serum IgG4 levels. AIP is a rare but distinct form of chronic pancreatitis. It has a unique clinical profile with two distinct subtypes. It commonly mimics pancreatic cancer in its presentation. There is no single diagnostic test to diagnose AIP, although there are typical radiological and biochemical profiles. AIP is exquisitely sensitive to corticosteroid treatment, but disease relapse is common.